GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (OTCPK:CMOPF) » Definitions » Net Interest Income

CMOPF (Cosmo Pharmaceuticals NV) Net Interest Income : $-0.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Cosmo Pharmaceuticals NV's net interest income for the six months ended in Jun. 2024 was $1.0 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.7 Mil.

Cosmo Pharmaceuticals NV Net Interest Income Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Net Interest Income Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.61 -8.71 -7.24 -6.71 -4.99

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.41 -3.29 -3.29 -1.68 0.98

Cosmo Pharmaceuticals NV Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo Pharmaceuticals NV Net Interest Income Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (OTCPK:CMOPF) » Definitions » Net Interest Income
Comparable Companies
BSP:BMKS3 BSP:PATL11 BSP:HCHG11 BSP:RSPD11 BSP:SNFF11 BSP:BALM3 BSP:FIQE3 BSP:CSUD3 BSP:TRPL3 BSP:HFOF11 LLY JNJ ABBV MRK XSWX:ROG LSE:AZN XSWX:NOVN AMGN PFE XPAR:SAN
Traded in Other Exchanges
COPNz:UK 0RGI:UK C43:Germany COPN:Switzerland
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Website
https://www.cosmopharma.com
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.